NASDAQ · STIMHealthcareSurgical Instruments

Neuronetics financials

$2.36−7.63%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$149.2M$74.9M$71.3M$65.2M$55.3M$49.2M$62.7M$52.8M
Gross profit$72.3M$54.2M$51.7M$49.7M$43.7M$37.7M$47.3M$40.3M
Gross margin48.5%72.3%72.5%76.3%78.9%76.5%75.4%76.4%
Operating income-$31.4M-$34.6M-$30.6M-$35.1M-$27.6M-$22.3M-$26.9M-$19.8M
Net income-$39.0M-$43.7M-$30.2M-$37.2M-$31.2M-$27.5M-$29.0M-$24.1M
Net margin−26.1%−58.4%−42.3%−57.0%−56.4%−55.7%−46.4%−45.7%
Diluted EPS$-0.59$-1.38$-1.05$-1.38$-1.22$-1.46$-1.58$-2.69
EBITDA-$28.0M-$32.5M-$28.5M-$33.5M-$26.5M-$21.4M-$25.9M-$19.0M
Operating cash flow-$20.4M-$31.0M-$32.0M-$30.7M-$28.0M-$28.4M-$30.5M-$20.5M
Free cash flow-$21.2M-$32.5M-$34.4M-$34.0M-$30.3M-$29.1M-$31.3M-$21.5M
Diluted shares66.0M31.7M28.7M26.9M25.5M18.8M18.4M8.9M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$28.1M$18.5M$59.7M$70.3M$94.1M$49.0M
Short-term investments$0.00$0.00$0.00$0.00——
Total debt$65.8M$55.2M$59.3M$36.0M$35.3M$34.6M
Total assets$141.6M$140.9M$115.8M$116.9M$141.2M$78.7M
Total liabilities$115.3M$109.1M$81.6M$59.8M$56.0M$53.2M
Shareholders' equity$26.2M$31.8M$34.2M$57.1M$85.2M$25.5M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology